Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of LY3839840 in Healthy Participants
NCT06153355Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3839840 in autoimmune diseases and inflammation (8 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) related to study drug. Started Dec 2023; status: completed.
02
Drugs
LY3839840
03
Conditions
autoimmune diseasesinflammation
Beyond the preview
Go deeper on NCT06153355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153355.